WO2000014204A1 - Recepteur de mort de cellules nerveuses - Google Patents
Recepteur de mort de cellules nerveuses Download PDFInfo
- Publication number
- WO2000014204A1 WO2000014204A1 PCT/JP1999/004771 JP9904771W WO0014204A1 WO 2000014204 A1 WO2000014204 A1 WO 2000014204A1 JP 9904771 W JP9904771 W JP 9904771W WO 0014204 A1 WO0014204 A1 WO 0014204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- app
- cell death
- cell
- antibody
- cells
- Prior art date
Links
- 230000030833 cell death Effects 0.000 title claims abstract description 285
- 210000002569 neuron Anatomy 0.000 title claims abstract description 115
- 108010049207 Death Domain Receptors Proteins 0.000 title description 4
- 102000009058 Death Domain Receptors Human genes 0.000 title description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 64
- 230000001939 inductive effect Effects 0.000 claims abstract description 64
- 230000004913 activation Effects 0.000 claims abstract description 41
- 239000000556 agonist Substances 0.000 claims abstract description 26
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 285
- 238000000034 method Methods 0.000 claims description 77
- 150000001875 compounds Chemical class 0.000 claims description 76
- 230000016273 neuron death Effects 0.000 claims description 50
- 238000012216 screening Methods 0.000 claims description 47
- 230000006698 induction Effects 0.000 claims description 44
- 230000003213 activating effect Effects 0.000 claims description 43
- 238000012360 testing method Methods 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 35
- 239000003112 inhibitor Substances 0.000 claims description 32
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 21
- 102000006255 nuclear receptors Human genes 0.000 claims description 21
- 108020004017 nuclear receptors Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 20
- 210000004556 brain Anatomy 0.000 claims description 17
- 210000005036 nerve Anatomy 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 14
- 230000001054 cortical effect Effects 0.000 claims description 12
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims description 11
- 230000003834 intracellular effect Effects 0.000 claims description 11
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims description 10
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims description 10
- 108091027981 Response element Proteins 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 8
- 210000004748 cultured cell Anatomy 0.000 claims description 7
- 108010057988 ecdysone receptor Proteins 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 14
- 208000015756 familial Alzheimer disease Diseases 0.000 abstract description 14
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000002609 medium Substances 0.000 description 34
- 239000011324 bead Substances 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 29
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 26
- 230000006907 apoptotic process Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000013467 fragmentation Methods 0.000 description 16
- 238000006062 fragmentation reaction Methods 0.000 description 16
- 108010024636 Glutathione Proteins 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 13
- 102000011727 Caspases Human genes 0.000 description 12
- 108010076667 Caspases Proteins 0.000 description 12
- KUXLVFFUSZCVHJ-YWDSYVAPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O KUXLVFFUSZCVHJ-YWDSYVAPSA-N 0.000 description 11
- 239000012190 activator Substances 0.000 description 11
- 238000013042 tunel staining Methods 0.000 description 11
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 10
- 108010066665 acetyl-aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 101710081950 Xaa-Pro aminopeptidase 2 Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 101710120037 Toxin CcdB Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000003061 neural cell Anatomy 0.000 description 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 229940123169 Caspase inhibitor Drugs 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 150000001299 aldehydes Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 2
- 108091061431 APP family Proteins 0.000 description 2
- 102000041248 APP family Human genes 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102100040055 Amyloid beta precursor like protein 1 Human genes 0.000 description 2
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 2
- 102000004018 Caspase 6 Human genes 0.000 description 2
- 108090000425 Caspase 6 Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 101000890407 Homo sapiens Amyloid beta precursor like protein 1 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100038364 Xaa-Pro aminopeptidase 2 Human genes 0.000 description 2
- 108010058883 acetyl-aspartyl-glutamyl-valyl-aspartyl-amino-4-methylcoumarin Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008316 intracellular mechanism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LPIARALSGDVZEP-SJVNDZIOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 LPIARALSGDVZEP-SJVNDZIOSA-N 0.000 description 1
- KYUFGGNCJRWMDN-GOYXDOSHSA-N (4s)-4-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2s,3s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(C)=O)C(C)C KYUFGGNCJRWMDN-GOYXDOSHSA-N 0.000 description 1
- 108091064702 1 family Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 102100036439 Amyloid beta precursor protein binding family B member 1 Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100264195 Caenorhabditis elegans app-1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000928670 Homo sapiens Amyloid beta precursor protein binding family B member 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000823042 Mus musculus Amyloid-beta precursor protein Proteins 0.000 description 1
- 101100491371 Mus musculus Aplp1 gene Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 229930186873 Ponasterone Natural products 0.000 description 1
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010052628 acetyl-valyl-isoleucyl-aspartyl-aldehyde Proteins 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000044945 human APLP2 Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 150000003102 ponasterones Chemical class 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
L'invention concerne un système déclenchant la mort de cellules avec une grande efficacité, dont la mise au point comporte les étapes consistant à préparer des cellules nerveuses présentant une expression stable et excessive d'APP (protéine précurseur amyloïde), et traiter ces cellules nerveuses à l'aide d'un agoniste d'APP. De plus, la mort cellulaire est déclenchée avec succès et avec une efficacité supérieure par la mise en oeuvre des étapes consistant à préparer un système de cellules nerveuses dans lequel l'expression d'APP mutée par la maladie d'Alzheimer familiale peut être déclenchée par un stimulus externe, et déclencher l'expression de l'APP mutée. L'utilisation de ces systèmes permet de cribler un médicament capable de réguler la mort cellulaire dans la maladie d'Alzheimer familiale et sporadique. Le médicament ainsi obtenu, qui inhibe la mort cellulaire par l'activation d'APP, est utile pour traiter des maladies, y compris la maladie d'Alzheimer, dans lesquelles intervient la mort de cellules nerveuses, et par conséquent où la mort de cellules nerveuses doit être inhibée.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU54483/99A AU5448399A (en) | 1998-09-04 | 1999-09-02 | Nerve cell death receptor |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25065698 | 1998-09-04 | ||
| JP10/250656 | 1998-09-04 | ||
| JP12325299 | 1999-04-28 | ||
| JP11/123252 | 1999-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000014204A1 true WO2000014204A1 (fr) | 2000-03-16 |
Family
ID=26460236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1999/004771 WO2000014204A1 (fr) | 1998-09-04 | 1999-09-02 | Recepteur de mort de cellules nerveuses |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5448399A (fr) |
| WO (1) | WO2000014204A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002253252A (ja) * | 2001-03-01 | 2002-09-10 | Otsuka Pharmaceut Co Ltd | 細胞傷害活性の測定法 |
| WO2006115026A1 (fr) | 2005-04-22 | 2006-11-02 | Japan Science And Technology Agency | Recepteur de l'humanine ou recepteur du polypeptide de type humanine |
| WO2007060715A1 (fr) * | 2005-11-22 | 2007-05-31 | The University Of Tokyo | Procédé de criblage d'un inhibiteur de la transduction du signal de l'interleukine-6 (il-6) |
| US7314864B1 (en) | 1999-09-17 | 2008-01-01 | Keio University | Humanin, a polypeptide suppressing neuronal death |
| EP2294413A2 (fr) * | 2008-06-12 | 2011-03-16 | Genentech, Inc. | Procédé de criblage pour identifier des composés qui inhibent la neurodégénérescence |
| JP2019083856A (ja) * | 2017-11-01 | 2019-06-06 | 国立研究開発法人産業技術総合研究所 | 脳表を局所的に損傷させる方法 |
-
1999
- 1999-09-02 WO PCT/JP1999/004771 patent/WO2000014204A1/fr active Application Filing
- 1999-09-02 AU AU54483/99A patent/AU5448399A/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| I. NISHIMOTO ET AL.: "A New Paradigm for Neurotoxicity by FAD Mutants of betaAPP: A Signaling Abnormality", NEUROBIOLOGY OF AGING, vol. 19, no. 1S, 1998, pages S33 - S38, XP002926150 * |
| ISAO NISHIMURA ET AL.: "Degeneration In Vivo of Rat Hippocampal Neurons by Wild-Type Alzheimer Amyloid Precursor Protein Overexpressed by Adenovirus-Mediated Gene Transfer", THE JOURNAL OF NEUROSCIENCE, vol. 18, no. 7, 1998, pages 2387 - 2398, XP002926149 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7314864B1 (en) | 1999-09-17 | 2008-01-01 | Keio University | Humanin, a polypeptide suppressing neuronal death |
| US7410757B1 (en) | 1999-09-17 | 2008-08-12 | Keio University | Method of screening disease depressant gene |
| JP4659236B2 (ja) * | 2001-03-01 | 2011-03-30 | 大塚製薬株式会社 | 細胞傷害活性の測定法 |
| JP2002253252A (ja) * | 2001-03-01 | 2002-09-10 | Otsuka Pharmaceut Co Ltd | 細胞傷害活性の測定法 |
| WO2006115026A1 (fr) | 2005-04-22 | 2006-11-02 | Japan Science And Technology Agency | Recepteur de l'humanine ou recepteur du polypeptide de type humanine |
| US8173771B2 (en) | 2005-04-22 | 2012-05-08 | Keio Univeristy | Humanin receptor or humanin-like polypeptide receptor |
| WO2007060715A1 (fr) * | 2005-11-22 | 2007-05-31 | The University Of Tokyo | Procédé de criblage d'un inhibiteur de la transduction du signal de l'interleukine-6 (il-6) |
| JP4882076B2 (ja) * | 2005-11-22 | 2012-02-22 | 国立大学法人 東京大学 | インターロイキン−６（ｉｌ−６）シグナル伝達阻害剤スクリーニング方法 |
| EP2294413A2 (fr) * | 2008-06-12 | 2011-03-16 | Genentech, Inc. | Procédé de criblage pour identifier des composés qui inhibent la neurodégénérescence |
| CN102124336A (zh) * | 2008-06-12 | 2011-07-13 | 健泰科生物技术公司 | 用于筛选抑制神经变性的化合物的方法 |
| EP2294413A4 (fr) * | 2008-06-12 | 2012-04-25 | Genentech Inc | Procédé de criblage pour identifier des composés qui inhibent la neurodégénérescence |
| JP2019083856A (ja) * | 2017-11-01 | 2019-06-06 | 国立研究開発法人産業技術総合研究所 | 脳表を局所的に損傷させる方法 |
| JP7071728B2 (ja) | 2017-11-01 | 2022-05-19 | 国立研究開発法人産業技術総合研究所 | 脳表を局所的に損傷させる方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5448399A (en) | 2000-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Peptides containing the RERMS sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite extension | |
| De Strooper et al. | Production of intracellular amyloid‐containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. | |
| Townsend et al. | Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers | |
| Link et al. | Somatodendritic expression of an immediate early gene is regulated by synaptic activity. | |
| Yamatsuji et al. | Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait‐linked phenotype. | |
| AU2003253044B2 (en) | Truncated tau proteins | |
| Moechars et al. | Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis | |
| Okamoto et al. | Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease. | |
| JP2000514178A (ja) | アミロイド―βペプチド（ｘ―≧４１）の生産を変更する能力についての化合物のスクリーニング | |
| JP4454230B2 (ja) | β−セクレターゼ基質及びその使用 | |
| Greenfield et al. | Cellular and molecular basis of beta-amyloid precursor protein metabolism | |
| WO2008051326A2 (fr) | Identification de contactines et de cams l1 en tant que ligands pour la protéine précurseur amyloïde | |
| Wu et al. | Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo | |
| KR20000075748A (ko) | 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계 | |
| Kojro et al. | Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease | |
| Sakai et al. | Expression of Nedd5, a mammalian septin, in human brain tumors | |
| WO2000014204A1 (fr) | Recepteur de mort de cellules nerveuses | |
| Efthimiopoulos et al. | Study of the phorbol ester effect on Alzheimer amyloid precursor processing: sequence requirements and involvement of a cholera toxin sensitive protein | |
| US20080038200A1 (en) | Model for neurodegenerative diseases involving amyloid accumulation | |
| US7407766B1 (en) | Screening method for agonists or antagonists of semaphorin 6C by determining the effect of a test compound on the interaction between semaphorin 6C and plexin-A1 | |
| Gomi et al. | MAP1B 1–126 interacts with tubulin isoforms and induces neurite outgrowth and neuronal death of cultured cortical neurons | |
| WO2006017386A2 (fr) | Intermédiaires de signalisation dans un modèle in vitro de la maladie d'alzheimer | |
| MXPA06003685A (es) | Animales trangenicos que presentan las alteraciones principales ligadas a la enfermedad de alzheimer. | |
| JP2009046459A (ja) | Ａｄｎｆ受容体 | |
| JP2012131711A (ja) | カルモジュリン様皮膚タンパク質を有効成分として含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 568951 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09786461 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |